Science Small Molecule Targeted Protein Degradation 
Broad Institute
MARCH 14, 2024
In one approach, they mark targeted proteins with “destroy me” tags that work with small molecules known as molecular glues to prompt the cell’s own protein-clearing machinery to gobble up the proteins. The new study appears in Science. Paper cited Mercer JAM, et al. March 14, 2024.
Drug Target Review
JULY 6, 2023
TPD is a rapidly evolving therapeutic modality to degrade a disease-causing proteins, thereby eliminating their function specifically. 1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional small molecules. How does TPD work?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Practical Cheminformatics
JANUARY 16, 2024
Following up on Part I and Part II, the third post in this series is a collection of review articles published in 2023 that I found helpful.
BMG Labtech
MAY 22, 2024
Options for cell-based protein degrader assays Interest is growing in the use of targeted-protein degradation to induce the breakdown of disease-causing proteins after treatment with small molecule drugs.
Drug Discovery World
JANUARY 15, 2024
Evotec will leverage its shared R&D platform to accelerate and de-risk the validation of targets, identification of drug candidates and successful completion of pre-clinical development activities up to IND. billion in contingent milestone payments for three target programmes.
BMG Labtech
APRIL 16, 2024
Promising future Molecular glues offer exciting opportunities for targeted protein degradation and new ways to reach some of the estimated 85% of undruggable targets in the proteome. Conventional drug development has often focused on finding small molecules that fit the active site of a protein.
Drug Discovery World
APRIL 6, 2023
Science ↔ Survivor Program As mentioned previously, AACR has a Scientist↔Survivor Program. Its purpose is to build enduring partnerships between the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide.
Expert insights. Personalized for you.
141 
Let's personalize your content